Compass Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary

• Compass Therapeutics Inc. CMPX.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of ten analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -14 cents to -9 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Compass Therapeutics Inc.'s reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $19.88 million.

• Compass Therapeutics Inc. shares had risen by 3.8% this quarter and gained 86.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Compass Therapeutics Inc. is $9.50, about 71.6% above its last closing price of $2.70

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)